{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:46Z","timestamp":1790792626216,"version":"4.1.0"},"reference-count":10,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-\u03b2-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2\/42) in the fingolimod group versus 2.3% (1\/44) in the interferon-\u03b2 group (odds ratio, 2.2; 95% confidence interval, 0.2\u201324.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-\u03b2-exposed pregnancies was 0.6 (95% confidence interval, 0.2\u20131.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.<\/jats:p>","DOI":"10.1177\/1352458520929628","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T11:40:37Z","timestamp":1592221237000},"page":"475-478","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study"],"prefix":"10.1177","volume":"27","author":[{"given":"Emmanuelle","family":"Pauliat","sequence":"first","affiliation":[{"name":"Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Onken","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Weber-Schoendorfer","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Rousson","sequence":"additional","affiliation":[{"name":"Center for Primary Care and Public Health, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Addor","sequence":"additional","affiliation":[{"name":"Department of Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baud","sequence":"additional","affiliation":[{"name":"Materno-Fetal and Obstetrics Research Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Th\u00e9audin","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Diav-Citrin","sequence":"additional","affiliation":[{"name":"The Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel\/The Hebrew University Hadassah Medical School, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Cottin","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Agusti","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Service, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-6610","authenticated-orcid":false,"given":"Victoria","family":"Rollason","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf C","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Terafar \u2013 Izmir Katip Celebi University Teratology Information, Research and Training Center, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Mothersafe, The Royal Hospital for Women, Sydney, NSW, Australia\/School of Women\u2019s and Children\u2019s Health, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Kadioglu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E","family":"Rothuizen","sequence":"additional","affiliation":[{"name":"Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Livio","sequence":"additional","affiliation":[{"name":"Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Panchaud","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Winterfeld","sequence":"additional","affiliation":[{"name":"Swiss Teratogen Information Service, Service de Pharmacologie Clinique, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"bibr1-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000137"},{"key":"bibr2-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418804760"},{"key":"bibr3-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002767"},{"key":"bibr4-1352458520929628","unstructured":"EUROCAT Central Registry University of Ulster. EUROCAT guide 1.4: Instruction for the registration of congenital anomalies, November 2019, https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/JRC-EUROCAT-Full-Guide-1.4-version-15-Nov-2019.pdf (accessed 30 January 2020)."},{"key":"bibr5-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr213"},{"key":"bibr6-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.02.015"},{"key":"bibr7-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.05.016"},{"key":"bibr8-1352458520929628","unstructured":"European Medicines Agency. Updated restrictions for Gilenya: Multiple sclerosis medicine not to be used in pregnancy, July 2019, https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/updated-restrictions-gilenya-multiple-sclerosis-medicine-not-be-used-pregnancy_en.pdf (accessed 30 January 2020)."},{"key":"bibr9-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0826"},{"key":"bibr10-1352458520929628","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517731913"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520929628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458520929628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520929628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:03:38Z","timestamp":1777694618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458520929628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1352458520929628"],"URL":"https:\/\/doi.org\/10.1177\/1352458520929628","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]}}}